Antonio Calles, Head of the Lung Cancer Unit at Ruber International Hospital, shared a post on X:
“Prof Yang presents final overall survival of MARIPOSA trial.
HR 0.75 (95% CI 0.61-0.92) Osimertinib 36.7 months vs not reached for Amivantamab and lazertinib.”
